Journal Club

20222021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011

 

2022

An All-Oral 6-Month Regime for Multidruf-Resistant TB (the Next Study): A Multicenter, Randomized Controlle

16.05.2022 (Justus Baarts)

Esmail A. et al.: An All-Oral 6-Month Regime for Multidruf-Resistant TB (the Next Study): A Multicenter, Randomized Controlled Trial AM J Respir Crit Care Med 2022 Vol. 205 P. 1214-1227

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

02.05.2022 (Gioele Capoferri)

Falcone M. et al.: Cefiderocol - Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii Antimicrob Agents Chemother 2022 

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection

11.04.2022 (Silvio Ragozzino)

Eckburg PB et al.: Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection N Engl J Med 2022 Vol. 386 P.1327-1338

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old

04.04.2022 (Anne-Valérie Burgener)

Ronen Arbel et al.: Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old Preprint. DOI: doi.org/10.21203/rs.3.rs-1478439/v1

Treatment outcome with penicillin G or cloxacillin in penicillin susceptible Staphylococcus aureus bacteraemia - A retrospective cohort study 

28.03.2022 (Benedikt Altermatt)

Hagstrand M. et al.: Treatment outcome with penicillin G or cloxacillin in penicillin susceptible Staphylococcus aureus bacteraemia - A retrospective cohort study International Journal of Antimicrobial Agents Vol. 59 Article 106567 2022

Relationship between serotypes, disease characteristics and 30‑day mortality in adults with invasive pneumococcal disease

21.03.2022 (Michelle Baumann)

Benadji A. et al.: Relationship between serotypes, disease characteristics and 30‑day mortality in adults with invasive pneumococcal disease Infection Vol. 50 P.223/233

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

28.02.2022 (Parham Sendi)

Hammond J et al.: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 N Eng J Med Online ahead of print. Feb 16. doi: 10.1056/NEJMoa2118542 2022

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

21.02.2022 (Ana Durovic)

CJL Murray et al.: Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis The Lancet Lancet 2022; 399: 629–55 2022

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge

14.02.2022 (Pascal Urwyler)

Killingley B. et al.: Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge Preprint, Research Square 2022

Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter Retrospective Cohort Study

07.02.2022 (Sandra Zingg)

Wald-Dickler N. et al.: Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter Retrospective Cohort Study Open Forum Infectious Diseases Volume 9, Issue 1 January 2022

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection

31.01.2022 (Gioele Capoferri)

Paul Feuerstadt et al.: SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection NEJM

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial

24.01.2022 (Carla Walti)

Avery RK et al:  Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial CID 2021

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

17.01.2022 (Silvio Ragozzino)

Gottlieb RL. Et al.: Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients N Engl J Med doi: 10.1056/NEJMoa2116846. Epub ahead of print. 2021

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

10.01.2022 (Andreas Neumayr)

Dunkle L.A. et al.: Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico NEJM DOI:10.1056/NEJMoa2116185 2021